Béa Fertility, a health tech startup developing at home care for those looking to start a family, has raised £2.5m.
Based in London, Béa has built what it describes as one of the first clinical-grade home treatments for fertility in the UK market.
The home kit developed by Béa has users carry out a treatment called Intracervical Insemination (ICI) which can be done in advance of extremely costly traditional processes such as IVF.
The company said ICI has shown 50% efficacy over six cycles of treatment, a major upgrade on the 27% success rate of IVF.
“Fertility impacts 1 in 6 couples, yet access to fertility care is severely lacking globally,” said Tess Cosad, CEO and co-founder of Béa Fertility.
Cosad said one of the primary goals of the startup is to widen the availability of fertility treatment, including bringing care to excluded groups.
“Fertility clinics have been selling the same expensive treatments for decades, yet there are a number of groups which remain underserved, including the LGBTQIA+ community, single people and parents experiencing secondary infertility.”
The round was led by Octopus Ventures and featured participation from JamJar and Forward Ventures as well as follow on investments from existing backers Calm/Storm and Q Ventures.
“When it comes to starting a family there are few things in life more meaningful than this,” said Kirsten Connell, an investor at Octopus Ventures.
“Béa Fertility who is reimagining the fertility care pathway, was a clear vision we wanted to get behind. We’re delighted to have joined Tess and her team on this journey.”
The startup previously raised £800,000 in a funding round in April 2021.